High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment.

BMC Cancer · 2015 · PMC4631086 · PMID 26525741

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

showed SLFN11 expression had an extremely significant positive correlation with response to Top1 inhibitors (topotecan and irinotecan), Top2 inhibitors (doxorubicin, mitoxantrone, etoposide), DNA alkylating agents (chlorambucil, melphalan, cisplatin), and DNA synthesis inhibitors (gemcitabine and fludarabine) [ 3 ].

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.